D. Chokshi

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

S. Jagannath, M. Dhodapkar, G. Yancopoulos, 2020, Blood.

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

S. Jagannath, G. Yancopoulos, I. Lowy, 2019, Blood.

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Y. Houvras, S. Jagannath, J. Dey, 2022, Blood.

MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma.

Y. Houvras, S. Jagannath, M. Dhodapkar, 2022, Clinical Lymphoma, Myeloma & Leukemia.

Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

S. Jagannath, M. Dhodapkar, A. Boyapati, 2021, Blood.

LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.

Y. Houvras, S. Jagannath, M. Dhodapkar, 2023, Journal of Clinical Oncology.